What is EWTX's current stock price?

EWTX (Edgewise Therapeutics, Inc.) is currently trading at $32.70 with a market cap of $3.52B.

What sector is Edgewise Therapeutics, Inc. in?

Edgewise Therapeutics, Inc. (EWTX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is EWTX a good stock to buy?

Analysts have a Buy consensus on EWTX with a price target of $42.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

EWTX Edgewise Therapeutics, Inc.

Healthcare

$32.70+0.03%ClosedMarket Cap: $3.52B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

7.10

P/S

0.00

EV/EBITDA

-18.60

DCF Value

$0.50

FCF Yield

-4.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-32.5%

ROA

-33.9%

ROIC

-40.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-49.0M	$—
Q4 null	$0.00	$-50.2M	$—
FY null	$0.00	$-167.8M	$—
Q3 null	$0.00	$-40.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$42.00

Target (Median)

$45.50

Target Range

$25.00 - $52.00

3 Strong Buy7 Buy2 Hold0 Sell0 Strong Sell

WedbushOutperform

2026-03-17

JP MorganOverweight

2026-03-17

Evercore ISI GroupOutperform

2026-02-27

JP MorganOverweight

2025-11-14

RBC CapitalOutperform

2025-11-07

Trading Activity

Insider Trades

View All

Donovan Joanne M.officer: CMO

SellTue May 05

Donovan Joanne M.officer: CMO

SellTue May 05

Donovan Joanne M.officer: CMO

SellTue May 05

Fox Jonathan Cdirector

SellFri Apr 03

Donovan Joanne M.officer: CMO

SellThu Apr 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.25

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Peers